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Background: Dietary treatment is helpful in CKD patients, but nutritional interventions are scarcely implemented.
The main concern of the renal diets is its feasibility with regards to daily clinical practice especially in the elderly
and co-morbid patients. This study aimed to evaluate the effects of a pragmatic, step-wise, personalized nutritional
support in the management of CKD patients on tertiary care.
Methods: This is a case-control study. It included 823 prevalent out-patients affected by CKD stage 3b to 5
not-in-dialysis, followed by tertiary care in nephrology clinics; 305 patients (190 males, aged 70 ± 12 years) received
nutritional support (nutritional treatment Group, NTG); 518 patients (281 males, aged 73 ± 13 years) who did not
receive any dietary therapy, formed the control group (CG). In the NTG patients the dietary interventions were
assigned in order to prevent or correct abnormalities and to maintain a good nutritional status. They included
manipulation of sodium, phosphate, energy and protein dietary intakes while paying special attention to each
patient’s dietary habits.
Results: Phosphate and BUN levels were lower in the NTG than in the CG, especially in stage 4 and 5. The prevalence
of hyperphosphatemia was lower in the NTG than in CG in stage 5 (13.3 % vs 53.3 %, p < 001, respectively), in stage 4
(4.1 % vs 18.3 % vs, p < 0.001) and stage 3b (2.8 % vs 9.5 % p < 0.05). Serum albumin was higher in NTG than in CG
especially in stage 5 . The use of calcium-free intestinal phosphate binders was significantly lower in NTG than in CG
(11 % vs 19 % p < 0.01), as well as that of Erythropoiesis stimulating agents (11 % vs 19 %, p < 0.01), and active Vitamin
D preparations (13 % vs 21 %, p < 0.01).
Conclusions: This case-control study shows the usefulness of a nutritional support in addition to the pharmacological
good practice in CKD patients on tertiary care. Lower phosphate and BUN levels are obtained together with
maintenance of serum albumin levels. In addition, a lower need of erythropoiesis stimulating agents, phosphate
binders and active Vitamin D preparations was detected in NTG. This study suggests that a nutritional support may be
useful in the management of the world-wide growing CKD burden.
Abbreviations: ACEi, Angiotensin-converting-enzyme inhibitor; ARB, Angiotensin II receptor blocker; BUN, Blood urea
nitrogen; CG, Control group; CKD, Chronic kidney disease; DBP, Diastolic blood pressure; EAA, Essential amino acid;
eGFR, estimated Glomerular Filtration Rate; ESA, Erythropoiesis stimulating agents; ESRD, End stage renal disease;
HDH, Healthy dietary habits; KA, Keto-acids; LPD, Low protein diet; ND, Normal diet; NTG, Nutritional Therapy Group;
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Nutritional therapy is a part of medical treatment of
pre-dialysis chronic kidney disease (CKD), and it is his-
torically related to manipulation of dietary protein intake
[1, 2]. The most frequently applied schemes include the
“low-protein” (0.6–0.7 g/Kg/day) diet or the “very low
protein” (0.4–0.3 g/Kg/day) diet supplemented with es-
sential amino acids and ketoacids [3]. Although relevant,
protein restriction is only one aspect of the dietary man-
agement of CKD patients. Additional aspects include
modifications in sodium, phosphorus and energy intake,
as well as in the source (animal or plant derived) of pro-
tein and lipids [4]. Information about processed foods
and home-based food preparations are additional modi-
fiable factors useful to modulate phosphate and sodium
effective load. As a whole, the aim of the nutritional sup-
port is to prevent or correct signs and symptoms of
renal failure, potentiate drug therapy, and to postpone
the initiation of dialysis while maintaining nutritional
status [5, 6]. Despite evidences that dietary treatment is
helpful in CKD patients, nutritional interventions are
scarcely implemented in renal clinics worldwide. Cur-
rently, the main concern of the renal diets is its feasibil-
ity with regards to daily clinical practice especially in the
elderly and co-morbid patients [6]. This point is particu-
larly timely due to changes of the features of CKD pa-
tients followed in the renal clinics. The prevalence of
diabetes and cardiovascular co-morbid conditions is in-
creasing as well as the age of the patients. A recent
epidemiological study in Italian renal clinics showed that
the mean age of pre-dialysis CKD patients was 71 years
[7]. It is noticeable that in the MDRD study (1992–1993),
the largest study on the effect of protein restriction in
CKD, the patients’ average age was 52–53 years old and
more importantly diabetics and patients older than
70 years were excluded [8]. So it is quite difficult to trans-
pose those data on the actual CKD population. The in-
creasing age of the CKD patients is associated with lower
spontaneous food intake which is also a function of the se-
verity of renal insufficiency [9]. Therefore a restrictive
dietary approach, mainly guided by the level of residual
renal function [3] may be not suitable to address the clin-
ical needs of the current CKD population and may be at
risk of protein-energy wasting.
Herewith we report a practical approach that we expe-
rienced in our renal nutrition clinic. It was based on the
assessment of the patient’s habitual energy and nutrients
intakes, in order to define the dietary interventions to
correct metabolic or nutritional abnormalities. Atten-
tion was payed to avoid dramatic changes in patient’s
eating behavior, to allow for greater chances of con-
cordance, adherence and quality of life. Moreover, nu-
tritional approach for CKD patients should include
psychosocial factors and behavioral aspects, such asparticipant knowledge, attitude, support, satisfaction,
self-monitoring and self-perception of success. The
rating of satisfaction of the dietary pattern affects pa-
tients adherence to the dietary prescriptions: a dietary
intervention that starts from medical recommenda-
tions, takes into account patients habits, needs and
lifestyle has more chances to guaranty a good adher-
ence to the dietary treatment in the long-term [10].
In this study we evaluated the effects of this pragmatic,
patient centered, step-wise nutritional support in the
management of CKD patients on tertiary care.
Methods
This is a case-control study. It included 823 prevalent
out-patients affected by CKD stage 3b to 5 not-in-
dialysis followed by tertiary care in nephrology clinics
in the period 2012–2015. Exclusion criteria were
eGFR >45 ml/min *1,73 m2, acute kidney injury, can-
cer, kidney transplanted patients, or patients on acute
illness or on immunosuppressive therapy.
Three hundred and five patients (190 males and 115
females, aged 70 ± 12 years) who received nutritional
counseling and were on dietary treatment in our CKD
clinic, for 6 months at least, formed the Nutritional
Treatment Group (NTG). The control group (CG) in-
cluded 518 patients (281 males and 237 females, aged
73 ± 13 years) who did not receive any nutritional sup-
port or dietary therapy: they were recruited from the
Italian Nefrodata Study cohort [7]. The Italian Nefrodata
is a multicentric, prospective, observational study con-
ducted in Italy. It included 1263 patients with CKD stage
3–5 on a tertiary care setting who were given good-
practice pharmacological therapy. From this cohort we
extracted the baseline data of the prevalent patients who
were not given any nutritional support. The prevalence
of diabetes was similar in the NTG (35.7 %) and in the
CG (34.4 %) as well as the prevalence of cardiovascular
co-morbidities (30.9 and 27.8 %, respectively).
Clinical and biochemical data were obtained from the
medical files. Biochemistry was performed using routine
lab methods.
The prevalent use of ACE-inhibitors or Angiotensin II
receptor blockers, furosemide, statins, allopurinol, calcium
carbonate and non-calcium containing phosphate binders,
active Vitamin D preparations and Erythropoiesis stimu-
lating agents (ESAs) was recorded in both groups.
A subgroup of 109 NTG patients was given the Dietary
Satisfaction Questionnaire, a 30 item form developed by
the MDRD Nutrition Coordinating Center at the Univer-
sity of Pittsburg, on the basis of a questionnaire of the
Case Western Reserve University [10]. It was completed
by the patients out of the dietician office. The purpose of
the Dietary Satisfaction Questionnaire was to assess the
patients’ feelings about their eating patterns, by questions
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meal preparation and planning and attitude to changes in
dietary habits [10]. The answers to the first item of the
Dietary Satisfaction Questionnaire was designed to assess
the overall satisfaction with diet: “Rate your overall satis-
faction with the way you are currently eating” In this
paper we report the prevalence of the patients’ responses
that were taken from 1 (dislike extremely) to 5 (like very
much). The responses of dislike extremely (1) and dislike
(2) were combined and referred as “dislike”, whereas liked
(4) and liked very much (5) were combined and reported
as “like”; the score 3 was considered as “neutral”. The
responses of the other items were well in keeping
with the first with regards to motivation in following
the diet, how many times the diet is observed, the
availability of finding food necessary for the diet and
the organization of the meals [10].
The NTG patients received nutritional support con-
sisting of a “step-wise “, personalized approach, by a
registered renal dietician [11]. Following the clinical
evaluation by the nephrologist, the renal dietitian
assessed dietary habits by a 3-day dietary recall, and per-
formed an intervention tailored to the needs and clinical
features of the patient. Currently, dietary prescriptions
were assigned not merely as a function of residual renal
function, but towards the correction of abnormalities (if
any) and to the maintenance of a good nutritional status.
As a preliminary objective, the patient was requested
to follow healthy dietary habits (HDH); in particular
suggestions were given to reduce salt intake and to limit
excess animal protein and phosphate intake.
The first step was to plan a “normal” diet (ND) that is a
diet that equals WHO recommendation for the general
population, namely a dietary protein intake of 0.8 g/Kg/d
and salt intake of 5–6 g per day [12, 13]. Grains, legumes
consumption was encouraged as well as vegetables and
fruits with some precautions in the case of hyperkalemia.
When the “normalization” of protein intake was not
enough to maintain a good metabolic control (i.e.
BUN < 50 mg/dl, serum phosphate < 4.0 mg/dl, bicar-
bonate > 23 mmol/l), dietary protein restriction was pro-
posed as the second step. A low protein diet (LPD)
supplying 0.6 g of proteins per Kg of body weight is
enough to cover protein needs provided that there is an
adequate amount of foods rich in high biological value
protein (meat, fish and white egg in particular), and an
adequate energy intake. For this reason the use of protein-
free products was generally recommended as they repre-
sent a source of energy without wasting products [14].
A low protein (0.7 g/Kg/day) vegan diet (VD) was an
alternative to the animal-based LPD [15–18]. In the
vegan diets the consumption of mixtures of grains and
beans is mandatory to guarantee a an adequate essential
amino acids intake [15].When more severe restrictions were needed to correct
the metabolic abnormalities, a very low protein (0.3–0.4 g/
Kg/day) diet (VLPD) was prescribed as the third step. The
VLPD needs supplementation of a mixture of essential
amino acids (EAA) and ketoacids (KA) and an energy in-
take that equals or even surpasses the energy requirement
[19]. At each level of dietary protein intake, phosphate in-
take was as low as possible, taking care to avoid processed
food and those containing preservatives, favoring plant-
origin food and using boiling as cooking method [20].
Protein-free products and EAA and KA represent useful
tools in the dietary management of CKD patients. Protein-
free products are useful for the safe and successful imple-
mentation of an animal-based LPD or a very low protein
diet for CKD patients. They represent a source of energy
from carbohydrates free from nitrogen, and with a low to
negligible content of potassium, sodium and phosphorus.
They are generally used for the implementation of low
protein diets but they can be used also as an additional
source of energy when needed [14].
The mixture of EAA and KA have generally been used
to supplement VLPD in patients with advanced CKD
but they can be also given when spontaneous protein in-
take results insufficient. For example it is a quite com-
mon finding that elderly people have monotonous
dietary habits that result in a spontaneous reduction of
protein and energy intake. In these cases, the priority is
to let them eat enough and to avoid restrictions while
the supplementation with EAA and KA is used to
achieve an adequate nitrogen intake to prevent/correct
protein-energy wasting.
As a general rule, patient’s dietary habits were modi-
fied as little as possible. In the case of low-nutrient
intake, which frequently occurs in elderly patients, sup-
plements or protein-free products can be added as
source of energy and/or EAA and KA can be prescribed
above patient’s habitual diet.
In the daily clinical practice, the role of the patient is
pivotal to obtain the success and safety that is expected
by these complex dietary approaches. So a proper coun-
seling is required for patient’s concordance and adher-
ence. Practical advice consists of defining the amount of
foods rich in animal proteins (using domestic measures),
reducing foods rich in salt (such as processed meats)
and dairy products, that are also rich in phosphorus. To
limit overly restrictive prescriptions, we address the fre-
quency of consumption. For example in those patients
who like cheeses (that have a high sodium and phos-
phate content), we suggested to eat cheeses once a week
or every 10 days instead of prohibiting them. This was a
well accepted approach and contributed to a better ad-
herence to nutritional therapy.
Boiling was suggested as the most useful method of
cooking to reduce the mineral content of foods [21].
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and appearance of foods. The use of olive oil, source of
healthy fats (to be limited in the case of overweight/
obesity), herbs and spices helps in achieving this goal.
Last but not least, strong recommendations were given
to avoid processed foods or foods and beverages with
phosphate-containing preservatives [22].
Patients following a VLPD were supplemented with
EAA and KA (1 tablet every 5 Kg of body weight). So-
dium bicarbonate or cholecalciferol where given when
metabolic acidosis or hypovitaminosis D were detected.
Low dose calcium carbonate (1 g/day) was supplemented
in the cases of low-phosphate diet because it is poor in
calcium, as well.Statistical analysis
Descriptive analysis is reported as Mean ± SD and percent-
age. Statistical analysis was performed by student’s t test
for unpaired data or chi-square test. Differences were con-
sidered as statistically significant when p < 0.05.Results
Within each CKD stage group, eGFR were very similar be-
tween the NTG and the CG patients. The prevalence of
diabetes or cardiovascular co-morbidities (myocardial in-
farction, cerebrovascular disease or obstructive lower-limb
vascular disease) by CKD stages is reported in Table 1.
Arterial blood pressure control was satisfactory and simi-
lar in both groups, at the same CKD stage (Table 1). At
the same eGFR level, BUN was lower in the NTG than in
the CG, especially in stage 4 and 5 (Table 1).
In the NTG, phosphatemia was lower than in CG at
all the stages of the disease (Table 1): the prevalence of
hyperphosphatemia (as defined as sP > 4.5 mg/dl) was
lower in the NTG than in the CG in stage 5 (53.3 % vs
13.3 %, p < 0.01, respectively), in stage 4 (18.3 % vs
4.1 %, p < 0.001) and stage 3b (9.5 % vs 2.8 %, p < 0.05).
Serum albumin was lower in the CG than in the NTG
especially in stage 5 (Table 1).
In the NTG stage 4 and 5 serum bicarbonate was well
controlled (24.7 ± 3.2 and 24.4 ± 2.3 mM, respectively);
unfortunately too many missing data in the CG pre-
vented a statistical comparison. Additional data regarding
hemoglobin, serum lipids, urate and BMI are reported in
Table 1, and they were roughly similar in NTG and CG.
The nutritional treatments by CKD stages are shown
in Fig. 1. As expected, the implementation of a LPD in-
creased from stage 3b (10.2 %) to stage 4 (60.2 %) and
stage 5 (91.4 %). In stage 3b a HDH and a ND are largely
prevalent. The VLPD was given in a few number of
patients, and in selected cases. Meanwhile, a number of
patients received EAA and KA supplementation on the
top of a LDP, when needed.The prevalence of CKD-related pharmacological treat-
ments by CKD stages in the NTG and in the CG is
reported in Fig. 2. As a whole, the prevalence of ACE-
inhibitors or Angiotensin II receptor blockers was simi-
lar as well as that of statins and allopurinol. Furosemide
therapy was less prevalent in the NTG than in the CG
(48.5 % vs 56 %, p < 0.05). The use of calcium-free phos-
phate binders was significantly lower in the NTG than
in the CG (19 % vs 11 %, p < 0.01). Similarly, the preva-
lence of Erythropoiesis stimulating agents (ESA) therapy
was significantly lower in the NTG than in the CG
(11 % vs 19 %, p < 0.01), as well as that of active Vitamin
D preparations (13 % vs 21 %, p < 0.01).
The results of the Dietary Satisfaction Questionnaire
showed that the majority of the patients were satisfied
with their diet (Fig. 3). The rating of LPD was similar to
that of ND (3.3 ± 1.0 vs 3.6 ± 0.89) patients. The preva-
lence of “dislike” was reported by 7.3 % of ND and by
13.1 % of LPD patients (Fig. 3). As expected, LPD pa-
tients had lower eGFR than ND patients (21.9 ± 8.3 vs
37.0 ± 10.5 ml/min*1.73 m2, p < 0.001).
Discussion
The results of the present investigation shows that a nu-
tritional support gives additional favorable effect on the
metabolic and clinical management of patients affected by
CKD 3b-5 and followed in tertiary care centers [5]. It is
the major reason why evidence exists that dietary treat-
ment can help to postpone the initiation of dialysis [6].
Both the NTG and the CG patients were followed in
tertiary care clinics so that good practice pharmaco-
logical therapies were guaranteed. Accordingly, blood
pressure control, level of PTH and hemoglobin, urate
and lipids were satisfactory and similar in both groups.
Meanwhile, parameters potentially affected by nutri-
tional intervention were significantly different. At the
same eGFR, BUN was lower in the NTG than in the
CG, especially in stage 4 and 5 where LPDs were largely
used. Similarly, serum phosphate levels were lower in
the NTG than in the CG, as well as the prevalence of
hyperphosphatemia. This occurred despite that fact that
the use of phosphate binders was more prevalent in the
CG patients. It is noteworthy that the prevalence of ESA
usage was lower in the NTG than in the CG at the same
(or even higher) hemoglobin levels. All these favorable
changes occur together with higher serum albumin
levels in NTG patients. In the CKD 4 subgroup, the
older age of the controls might contribute to low albu-
min levels. However, lower albumin levels in the control
group were even more evident in CKD 5, where no dif-
ference of age exists.
The term “nutritional therapy” holds the potential to en-
sure that no patient is excluded and intervention is based
on the individuation of the single patient’s nutritional
Fig. 1 The types of nutritional treatments in the patients of Nutritional Therapy Group, by CKD stages HDH (healthy dietary habits), ND (normal diet),
LPD (low protein diet), VLPD (very low protein diet)
Table 1 Age, Body Mass Index, Arterial blood pressure values and biochemistry in Nutritional Therapy Group (NTG) and Control
Group (CG) patients by CKD stages
Stage













Age, yrs 70 ± 13 73 ± 12 71 ± 11** 74 ± 13 69 ± 17 69 ± 15
Diabetes, % 34.0 39.6 41.3 31.3 22.5 19.2
CV Morbidity, % 33.1 31.1 31.0 25.9 22.5 19.2
BMI, kg/m2 27.9 ± 4.0 28.3 ± 4.7 27.6 ± 5.3 27.7 ± 5.7 26.9 ± 6.5 26.1 ± 4.1
SBP, mmHg 138 ± 18** 131 ± 17 135 ± 16 133 ± 20 136 ± 29 137 ± 20
DBP, mmHg 79 ± 10* 74 ± 10 75 ± 11*** 73 ± 10 78 ± 14 77 ± 8
PP, mmHg 59 ± 17 58 ± 15 60 ± 15 61 ± 19 58 ± 20 61 ± 18
eGFR, ml/min*1.73 m2 38.2 ± 5.1 36.8 ± 4.1 23.4 ± 4.1 23.3 ± 4.1 12.0 ± 2.6 12.0 ± 2.1
BUN, mg/dl 33.8 ± 9.5 36.7 ± 11.4 41.9 ± 15.2* 49.5 ± 17.1 49.0 ± 24.3* 72.3 ± 16.2
Calcium, mg/dl 9.4 ± 0.5 9.3 ± 0.9 9.4 ± 0.5 9.3 ± 0.7 9.3 ± 1.5 9.1 ± 0.9
Phosphate, mg/dl 3.3 ± 0.6* 3.6 ± 0.7 3.6 ± 0.5** 3.9 ± 0.9 3.9 ± 1.2* 4.7 ± 1.0
PTH, pg/ml 108 ± 65 116 ± 103 160 ± 100 150 ± 112 232 ± 138 154 ± 140
Sodium, mEq/l 140 ± 2 141 ± 3 140 ± 2 140 ± 4 140 ± 2 140 ± 3
Potassium, mEq/l 4.7 ± 0.4 4.7 ± 0.6 4.7 ± 0.6 4.8 ± 0.6 4.6 ± 0.4 4.9 ± 0.8
Haemoglobin, g/dl 13.2 ± 1.8 12.7 ± 1.7 12.2 ± 1.4*** 11.8 ± 1.5 11.4 ± 2.0 11.5 ± 1.4
Haematocrit, % 40.3 ± 5.2*** 38.5 ± 4.9 37.3 ± 4.2*** 36.2 ± 4.8 35.3 ± 6.3 35.7 ± 4.8
Albumin, g/dl 4.1 ± 0.4*** 3.9 ± 0.4 4.1 ± 0.4* 3.8 ± 0.4 4.1 ± 0.8** 3.7 ± 0.6
Total cholesterol, mg/dl 178 ± 36 178 ± 42 183 ± 40 177 ± 43 175 ± 49 165 ± 42
LDL cholesterol, mg/dl 100 ± 32 106 ± 34 102 ± 32 99 ± 34 98 ± 32 88 ± 29
HDL cholesterol, mg/dl 51 ± 17 52 ± 29 53 ± 23 49 ± 15 48 ± 17 44 ± 16
Triglycerides, mg/dl 141 ± 68 145 ± 77 151 ± 87 148 ± 76 144 ± 76 133 ± 75
Urate, mg/dl 6.3 ± 1.5 6.1 ± 1.8 6.7 ± 1.9* 5.8 ± 1.9 6.3 ± 3.0 6.0 ± 3.0
Abbreviations: BMI (body mass index), BUN (blood urea nitrogen), DBP (diastolic blood pressure), PP (pulse pressure), SBP (systolic blood pressure)
*: p < .001; **: p < .01; ***: p < .05 vs CG
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Fig. 2 Prevalence of CKD-related pharmacological therapies in the NTG (dark columns) and in the CG (grey columns) by CKD stages
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frequent practice in many parts of the world. In a recent
survey in Italy, nutritional prescriptions were given to
54.8 % of patients with CKD stage 4 and to 65.9 % of pa-
tients with CKD stage 5 [7].
A restrictive or schematic approach, mainly based on
eGFR level, may remain suitable in the younger cohort
of CKD patients generally characterized by a nearly nor-
mal/high food intake, which likely induces metabolic ab-
normalities in the presence of moderate to severe renal
insufficiency. In contrast, especially for elderly patients,it is quite prevalent to observe an under-nutrition pat-
tern with only small increment of phosphate and urea
serum levels: therefore special focus must be given to
the energy intake in the elderly and/or frail patients.
A proper nutrition in CKD patients is able to correct
or prevent signs, symptoms and complications of CKD,
to delay the start of dialysis, and to prevent malnutrition.
However, not all the patients have the same nutritional
concerns and need the same intervention. The diet must
be tailored to the single patient and the efficacy and
safety of the diet is largely dependent on its feasibility.
Fig. 3 Prevalence of the responses to the question “Rate your overall satisfaction with the way you are currently eating”. The answers “dislike
extremely” (score 1) and “dislike” (score 2) were combined and referred to as “Dislike”; the answers “Like very much” (score 5) and “like” (score 4) were
combined and referred to as “Like”; the rating 3 was considered as “Neutral”. Results are reported for all the 109 subject, and separately for low protein
diet (LPD) and for normal diet (ND) patients
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changes should be targeted to obtain specific goals (i.e.
lowering urea production and/or lowering phosphate
load, and/or modulation of sodium and energy intake,
and so on…). During the follow up we adjusted the diet
according to clinical, nutritional and biochemistry evalu-
ation. In our experience with this approach patients’ ad-
herence increases as their habits are not completely
disrupted but gradually changed.
This approach particularly fits to the elderly patient who
often have several barriers preventing correct feasibility of
the dietary prescriptions such as socio-economic prob-
lems, chewing difficulties, scarce appetite, solitude or de-
pression. In these cases, under-nutrition is quite prevalent
so the priority is to increase food intake and energy intake,
rather than restricting phosphate or protein intake, that is
preventing malnutrition.
The NTG patients were given ND-LPD-VLPD or
changes limited to energy, and/or sodium and/or phos-
phate when needed to correct metabolic or clinical ab-
normalities. As a whole, the distribution of the type of
the nutritional therapy (as classified by protein content)
is reported in Fig. 1.
We usually start from the existing dietary habits and
we implement gradual changes to obtain the requested
targets, using both written recommendations and visual
tools that can be more impressive.
In practice, the first step consists of general advice to
implement a healthy diet and to control salt and phos-
phate intakes avoiding high protein intake, in order to
achieve normalization of protein and salt intake (0.8 g/Kg/
day and 6 g/day respectively) according to the WHOrecommendations for the general population [12, 13]. Low
protein or very low protein regimens are prescribed as
needed [3, 5] usually when residual renal function is critic-
ally reduced and overt metabolic abnormalities arise. It is
noteworthy that, at the same protein intake, special atten-
tion has been paid to limit phosphate load as much as
possible, especially to avoid processed food and products
containing phosphate-based preservatives [20]. Energy
prescription was dependent on requirement and protein
intake. For those on protein restricted regimens, energy
intake must equal or even overcome the energy re-
quirement, including overweight or obese patients.
Conversely, when low-energy intake regimens are ne-
cessary, protein intake must not be restricted as to
avoid the risk of negative nitrogen balance [23].
Our findings are in keeping with previous reports which
demonstrated favorable effects of renal diets [24–27]. The
novelty of this paper is found in the implementation of a
personalized, step-wise nutritional approach, that is tai-
lored to the needs of the individual patient and designed
to obtain specific nutritional targets.
Information coming from the Dietary Satisfaction
Questionnaire was interesting . Patients reported a good
rating of satisfaction with their diet, with a dislike rating
reported by only 1 out of 10 patients. LPD patients
showing a worse satisfaction than ND patients, likely be-
cause of more restricted protein intake and food choices
due to the more severe residual renal function, and to
the use of protein-free products. Patients on ND (0.8 g
protein /Kg/day) were more satisfied with taste and fla-
vor and the variety of the food eaten and stated they
have no problems in finding food required for the diet
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The majority of patients reported to have no difficulties in
organizing their meals but LPD had more problems in eat-
ing out at restaurant or at someone’s home. Patients stated
to be highly motivated to follow the diets with a higher
percentage for LPD (90 vs 83.3 %) and to follow the diet
at every meal (88.3 vs 69.7 %, p < 0.05): the more advanced
CKD and the fear of dialysis commencing may account
for these results. The low rating of “dislike” as regards the
satisfaction of the eating pattern, 7.3 % for the ND patients
and 13.1 % for the LPD patients, is encouraging as the
success and safety of dietary treatment is related to the pa-
tients’ adherence and this is strictly related to their rating
of satisfaction with the dietary patterns [10].
Finally, lower use of erythropoiesis stimulating agents,
phosphate binders and active Vitamin D preparations
was detected in NTG. Additional ad hoc studies are
needed to confirm a favorable cost-effectiveness effect of
the nutritional support [28].
The limitations of the study are mainly related to de-
sign and measurements.
The study is case-control and can not give the evidence
of a randomized controlled trial. However, a case-control
study allows interpretative evaluations of similar topics
and of two different groups. Not all nephrology units are
able to deliver nutritional interventions, but the activities
of this clinic experience could be replicated.
It is possible that, in part at least, the NTG group
looked better because the patients were more compliant
or had a more receptive attitude to dietary intervention:
however, nutritional support requires the active role of
the patient to be effective and safe. The main reason
why the CG patients did not receive any nutritional sup-
port was the lack of a renal dietician service, and the fact
that physicians doubt the usefulness of the approach as
well as the patient’s adherence. The two groups were
very similar regarding eGFR levels and co-morbidities,
and all patients were clinically stable and studied out of
periods of acute illness.
The pharmaco-economic aspects were not addressed
directly, but it is reasonable that nutritional support
could reduce drug cost burden [28–30]. We hope that
this study will stimulate further studies able to assess the
cost-benefit of nutritional therapy.
Conclusions
In summary, this case-control study shows the useful-
ness of a nutritional support in addition to the pharma-
cological good practice in CKD patients on tertiary care.
At the same residual renal function, lower phosphate
and BUN levels were obtained together with mainten-
ance of serum albumin. In addition, a lower need of
erythropoiesis stimulating agents, phosphate binders and
active Vitamin D preparations was detected in NTG.This study suggests that a nutritional support may be
useful in the management of the world-wide growing
CKD burden.
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